July 2013

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with DTIC and immunotherapy with HD IL-2 or interferon-α.

A quick reference chart of the key clinical trials presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Max S. Wicha, MD, was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

Cancer strikes fear as a clinical diagnosis. It also keeps employer medical directors up at night, wondering what the future will bring in the context of the limited dollars available for all medical care and diseases.

Three presentations from the ASCO 2013 Annual Meeting extended positive findings comparing nab-paclitaxel and gemcitabine to gemcitabine in 861 untreated patients with advanced pancreatic cancer.

The US Supreme Court’s unanimous ruling that an individual’s genes cannot be patented, together with Angelina Jolie’s announcement of her prophylactic double mastectomy, have focused much attention on cancer genetic testing.

Adding the BTK inhibitor ibrutinib to standard rituximab (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100%.

Salvage therapy combining the novel Hsp90 inhibitor ganetespib with docetaxel significantly improved OS in some patients with NSCLC in the phase IIb/III GALAXY- 1 trial.